Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, Minnesota, USA; Center for Infectious Disease Research and Policy, C315 Mayo Memorial Building, MMC 263, 420 Delaware Street, SE, Minneapolis, Minnesota 55455, USA.
Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, Minnesota, USA.
Vaccine. 2023 Mar 24;41(13):2101-2112. doi: 10.1016/j.vaccine.2023.02.032. Epub 2023 Feb 21.
Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.
广谱保护性冠状病毒疫苗是预防未来 SARS-CoV-2 变体的重要工具，对于减轻新型冠状病毒引起的未来爆发或大流行的影响可能发挥关键作用。冠状病毒疫苗研发（R&D）路线图（CVR）旨在促进此类疫苗的开发。该 CVR 由比尔及梅琳达·盖茨基金会和洛克菲勒基金会资助，通过协作和迭代过程产生，由明尼苏达大学传染病研究与政策中心（CIDRAP）牵头，涉及 50 名国际主题专家和该领域的知名领导者。本报告总结了 CVR 中概述的主要问题和研究领域，并确定了高优先级的里程碑。CVR 涵盖 6 年的时间框架，分为五个主题领域：病毒学、免疫学、疫苗学、动物和人体感染模型以及政策和融资。每个主题领域都包括关键障碍、差距、战略目标、里程碑和其他研发重点。路线图包括 20 个目标和 86 个研发里程碑，其中 26 个被列为高度优先事项。通过确定关键问题和解决这些问题的里程碑，CVR 为指导促进广谱保护性冠状病毒疫苗开发的资金和研究活动提供了框架。
